Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores
| Autor: | Giovanni Targher, Ke Hua Pan, Ming-Hua Zheng, Christopher D. Byrne, Hua Dong Yan, Kenneth I. Zheng, Qing-Feng Sun, Xiao Bo Wang, Yong-Ping Chen, Alessandro Mantovani, Mohammed Eslam, Jacob George |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Coronavirus disease 2019 (COVID-19) Pneumonia Viral Disease Gastroenterology 03 medical and health sciences Betacoronavirus 0302 clinical medicine advanced NAFLD Fibrosis Non-alcoholic Fatty Liver Disease Internal medicine Medicine Humans nonalcoholic steatohepatitis Pandemics Retrospective Studies business.industry SARS-CoV-2 Fatty liver COVID-19 Retrospective cohort study medicine.disease Obesity 030104 developmental biology Liver 030211 gastroenterology & hepatology Steatosis business Viral hepatitis Coronavirus Infections |
| Zdroj: | Gut |
| Popis: | A recent study reported that patients with severe COVID-19 were more likely to have non-alcoholic fatty liver disease (NAFLD) compared with those with non-severe COVID-19 illness.1 However, the prognosis of NAFLD (recently renamed metabolic dysfunction-associated fatty liver disease (MAFLD)2) is determined by the severity of liver fibrosis.3 4 We therefore postulated that patients with MAFLD with increased non-invasive liver fibrosis scores are at higher risk of severe illness from COVID-19. We studied 310 patients with laboratory-confirmed COVID-19 who were consecutively hospitalised at four sites in Zhejiang Province, China, between January and February 2020. Some of these patients (n=150) have been included in a prior study examining the association between obesity and COVID-19 severity.5 Patients with viral hepatitis, excessive alcohol consumption, chronic pulmonary diseases or active cancers were excluded. Clinical and laboratory data were collected at hospital admission. All patients were screened for hepatic steatosis by computed tomography and subsequently diagnosed as MAFLD.6 The originally validated cut-points for fibrosis-4 (FIB-4) index and NAFLD fibrosis score (NFS) were used to categorise liver fibrosis probability … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|